Phone Number: +1 4164352602
YONG YAO
Senior Advisor
A highly accomplished financial executive with over 25 years of leadership experience spanning investment banking, financial accounting, biomedical/biotech/biopharma innovation, consulting, strategic business management, logistics & supply chain management, and real estate. Mr. Yao brings various industrial experiences and financial leadership, with expertise in financial accounting, operations, strategic budgeting, business transformation, and planning across sectors including life sciences, capital markets, and supply chain.
Mr. Yao is also an experienced management consultant and board advisor, having supported numerous companies in M&A transactions, fundraising, financial strategy, business development, and IPO readiness. As an entrepreneur, he co-founded SelecIn Biomedical Inc., where he led early-stage development of first-in-class small molecule anti-tumer drugs and secured significant private funding.
He has held CFO and executive roles at public and private companies in North America and Asia, including Mountain Valley MD Holdings Inc. (CSE: MVMD.CN, OTCQB: MVMDF), Hanalytics BioMind, and Xinyuan Real Estate Corp. (NYSE: XIN). Previously, Mr. Yao also served in senior management roles at Scotiabank, Morgan Stanley, and Bank of America Merrill Lynch, where he led initiatives across finance, compliance, and deal transactions. He has also served as CFO and Executive Vice President of Lobe Sciences Inc. (CSE: LOBE.CN; OTCQB: LOBEF) and fractional CFO of ASEA Group, and currently sits on the board of PSIG Group (NASDAQ: PSIG) as an Independent Director and Chair of the Audit Committee.
Mr. Yao holds an MBA from McGill University, a Bachelor of Science in Biology from Nankai University, and is designated as a Fellow Chartered Management Accountant (FCMA, UK) and Chartered Global Management Accountant (CGMA, AICPA-CIMA).
Mr. Yao is also an experienced management consultant and board advisor, having supported numerous companies in M&A transactions, fundraising, financial strategy, business development, and IPO readiness. As an entrepreneur, he co-founded SelecIn Biomedical Inc., where he led early-stage development of first-in-class small molecule anti-tumer drugs and secured significant private funding.
He has held CFO and executive roles at public and private companies in North America and Asia, including Mountain Valley MD Holdings Inc. (CSE: MVMD.CN, OTCQB: MVMDF), Hanalytics BioMind, and Xinyuan Real Estate Corp. (NYSE: XIN). Previously, Mr. Yao also served in senior management roles at Scotiabank, Morgan Stanley, and Bank of America Merrill Lynch, where he led initiatives across finance, compliance, and deal transactions. He has also served as CFO and Executive Vice President of Lobe Sciences Inc. (CSE: LOBE.CN; OTCQB: LOBEF) and fractional CFO of ASEA Group, and currently sits on the board of PSIG Group (NASDAQ: PSIG) as an Independent Director and Chair of the Audit Committee.
Mr. Yao holds an MBA from McGill University, a Bachelor of Science in Biology from Nankai University, and is designated as a Fellow Chartered Management Accountant (FCMA, UK) and Chartered Global Management Accountant (CGMA, AICPA-CIMA).
Education
MBA McGill University, Montreal, Quebec, Canada
Top CFO Certificate in Accounting, Shanghai University of Finance and Economics, China
Bachelor of Science in Biology, Nankai University, Tianjin, China
FCMA Fellow Chartered Management Accountant, CIMA UK
CGMA Chartered Global Management Accountant, AICPA & CIMA
Certified Fund Manager China CSRC Securities Fund Association
LLQP Certificate Ontario Life License Qualification Program (Life Insurance)
Top CFO Certificate in Accounting, Shanghai University of Finance and Economics, China
Bachelor of Science in Biology, Nankai University, Tianjin, China
FCMA Fellow Chartered Management Accountant, CIMA UK
CGMA Chartered Global Management Accountant, AICPA & CIMA
Certified Fund Manager China CSRC Securities Fund Association
LLQP Certificate Ontario Life License Qualification Program (Life Insurance)
Experience
CFO and Executive Vice President, Lobe Sciences Ltd.
CFO and Board Director, ASEA Group
Independent Director & Chair of Auditing Committee, PSIG
CFO, MVMD
CFO and Board Director, Hanalytics BioMind Inc.
Executive Director, Xinyuan Real Estate Corp.
Country CFO, Bank of America Merrill Lynch
Vice President, Country COO, Morgan Stanley
Senior Manager, Scotiabank
CFO and Board Director, ASEA Group
Independent Director & Chair of Auditing Committee, PSIG
CFO, MVMD
CFO and Board Director, Hanalytics BioMind Inc.
Executive Director, Xinyuan Real Estate Corp.
Country CFO, Bank of America Merrill Lynch
Vice President, Country COO, Morgan Stanley
Senior Manager, Scotiabank
Track Record
Fundraising of 7 million CAD for ASEA Group (4 million from PE, and 3 million from Bank), and finished one M&A transaction.
Established a clear taxation map of various legal entities for LATAM countries
Three-round fundraising of USD250 million to Hanalytics BioMind, enhanced company’s valuation from USD10 million to USD1.4 billion, created the financial accounting department from 1 people to 25 employee globally. Finished three M&A transactions for Hanalytics BioMind.
Created and managed three acquisition funds with total of CNY30 billion for land acquisition and real estate projects.
Sucessfully advised over 10 companies with respect to fundraising, M&A, IPO preparation, finance restructuring, and accounting SOPs.
Being an entrepreneur of biomedical start-up company to develop anti-cancer drugs and secure VC investment of CNY35 million.
Established a clear taxation map of various legal entities for LATAM countries
Three-round fundraising of USD250 million to Hanalytics BioMind, enhanced company’s valuation from USD10 million to USD1.4 billion, created the financial accounting department from 1 people to 25 employee globally. Finished three M&A transactions for Hanalytics BioMind.
Created and managed three acquisition funds with total of CNY30 billion for land acquisition and real estate projects.
Sucessfully advised over 10 companies with respect to fundraising, M&A, IPO preparation, finance restructuring, and accounting SOPs.
Being an entrepreneur of biomedical start-up company to develop anti-cancer drugs and secure VC investment of CNY35 million.
International Experience
Canada (CA)
China (CN)
Singapore (SG)
United States of America (US)
China (CN)
Singapore (SG)
United States of America (US)
Sector Expertise
Pharmaceutical industry
Financial Services
Manufacturing industry
Real Estate Activities
Financial Services
Manufacturing industry
Real Estate Activities
Keywords
M&A IPO Fundraising PE and VC Capital Strategic Finance Business Development Financial reporting and accounting Regulation and Compliance
